Navigation Links
Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia
Date:2/14/2012

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced the Therapeutic Goods Administration (TGA) division of the Australian government has approved the Delcath Hepatic CHEMOSAT® Delivery system for listing on the Australian Register of Therapeutic Goods (ARTG).  The TGA's approval allows Delcath to market and sell the system in Australia.

"Regulatory approval in Australia represents another achievement for Delcath as we seek to expand the global addressable markets for our CHEMOSAT system," said Eamonn P. Hobbs, President and CEO of Delcath.  "We believe chemosaturation therapy via our CHEMOSAT system will provide an important treatment alternative for liver cancer patients in the Australian market."

Delcath received CE Marking for CHEMOSAT in April 2011 in the European Union, allowing Delcath to market and sell the product in countries in the European Economic Area.  In October 2011, Delcath completed the product notification process through its designated sponsor for the CHEMOSAT system with the Medicines and Medical Device Safety Authority in New Zealand.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the Company's ability to successfully enter into a distribution agreement and commercialize the CHEMOSAT system in Australia and any corresponding revenue, CE Marking for the Generation Two system and the timing of our commercial launch in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system in any market, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information: Investor Contact:

Media Contact:Doug Sherk/Gregory Gin

Janine McCargoEVC Group

EVC Group415-568-4887/646-445-4801

646-688-0425 


'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcaths Ireland Operations Achieves ISO 13485 Certification
2. Delcath Announces Agreement With the Frankfurt University Hospital for Launch of Hepatic CHEMOSAT Delivery System in Germany
3. Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
4. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
5. Delcath to Present at the Lazard Healthcare Conference on November 15
6. Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
7. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
8. FDA Schedules Delcath Pre-New Drug Application Meeting Date
9. Delcath Announces Completion of Regulatory Notification Process in New Zealand
10. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
11. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... -- Pharmaceutical giant Johnson & Johnson has ... who says its talc-based powder products caused ovarian cancer. ... $5 million in compensatory damages and $50 million in ... ) , This is the second in ... the same court awarded $72 million to the family ...
(Date:5/3/2016)... Intec Pharma Ltd. (NASDAQ: ... today announced the appointment of Pnina Strauss-Levy ... "Ms. Strauss-Levy has 15 years of experience in clinical ... track record, having supported the advancement of several products ... the United States and ...
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... ... Elizabeth Murray has always loved walking one to two miles a day. She ... one on her arm. But she got to the point where she could barely ... The valves of the heart wouldn’t close properly resulting in mitral regurgitation, where blood ...
(Date:5/3/2016)... ... May 03, 2016 , ... Excessive panting in the ... pet anxiety. "Pet owners often think anxiety only manifests itself as trembling or ... other ways, and there’s things that be done about it,” says Dr. Jim Lowe, ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... selected by Tidelands Health, a three hospital system in South Carolina, to provide ... the lookout for technology that enhances communication, drives workflow efficiencies and improves provider ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today ... tough medical situations or practice tricky or rare procedures in an environment that looks ... SIM Center is also available to inventors and “hackers” to develop and test new ...
(Date:5/3/2016)... ... 2016 , ... Each year, about 800,000 people suffer from cerebral vascular accidents, ... and account for one death every four minutes. Many people who survive a ... is launching a video series called “Your Brain,” in conjunction with its medical journal ...
Breaking Medicine News(10 mins):